TKI Therapy in CML: Emerging Treatments, Ensuring Safety

Access Activity

Overview / Abstract:

This Virtual Practice summarizes advances in tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) in the context of disease- and patient-specific characteristics; reviews the most effective methods for monitoring early response and long-term therapeutic outcomes; assesses the milestones and mutational analyses to identify when a change in TKI therapy is needed; compares toxicity profiles of the currently available TKI agents; and examines how toxicity could interact with a patient’s pre-existing comorbidities and influence adherence and outcomes.

Intended Audience
This activity has been designed to meet the educational needs of hematologists, medical oncologists, health system pharmacists, oncology nurses, nurse practitioners, physician assistants, and other health care professionals involved in the care of patients with CML.

Educational Objectives:
Upon completion of this activity, participants should be able to:
• Summarize recent treatment advances for CML and their potential implications for clinical practice
• Explain current clinical evidence on treatment goals and monitoring steps for patients with chronic-phase CML receiving TKI therapy
• Select treatment in the frontline setting based on current clinical evidence and disease- and patient-specific characteristics to maximize the likelihood of achieving complete molecular remission/cytogenetic remission
• Recognize differences in the toxicity profile among TKIs and the impact of these differences in tailoring treatment for the individual patient


Oct 31, 2019


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME



Credits / Hours

Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and RedMedEd. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement: Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Presenters / Authors / Faculty

Elias Jabbour, MD—Program Chair
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Michael W. Deininger, MD, PhD
Chief, Division of Hematology/Hematologic Malignancies
Huntsman Cancer Institute
M. M. Wintrobe Professor of Medicine
Senior Director of Transdisciplinary Research
University of Utah
Salt Lake City, Utah

Jerald Patrick Radich, MD
Member, Clinical Research Division
Fred Hutch
Professor of Medicine
University of Washington
Seattle, Washington

Activity Specialities / Related Topics

Education / Teaching, Hematology, Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

Support for this activity has been provided through an educational grant from Pfizer.

Keywords / Search Terms

RedMedEd Einstein, RedMedEd, Free CME, CME, CE Free, chronic myeloid leukemia, CML, tyrosine kinase inhibitor, TKI, first-generation, second- and third-generation, second-generation, third-generation, side-effect, treatment advances, chronic, molecular remission/cytogenetic remission, toxicity profile, tailoring treatment, frontline Free CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.